Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
about
Administered paricalcitol dose and survival in hemodialysis patients: a marginal structural model analysisMineral and bone disorders and survival in hemodialysis patients with and without polycystic kidney diseaseCalciphylaxis in chronic renal failure: An approach to risk factorsKidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals.Exploring the effect of parathyroidectomy for tertiary hyperparathyroidism after kidney transplantation.Antibacterial responses by peritoneal macrophages are enhanced following vitamin D supplementation.Treatment of secondary hyperparathyroidism in kidney disease: what we know and do not know about use of calcimimetics and vitamin D analogs.Effect of VDRA on survival in incident hemodialysis patients: results of the FARO-2 observational studyVascular endothelial function is not related to serum uric acid in healthy adults.26-Desmethyl-2-methylene-22-ene-19-nor-1α,25-dihydroxyvitamin D3 compounds selectively active on intestine.Vitamin D signaling pathway plays an important role in the development of heart failure after myocardial infarction.Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden.Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients.Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients.Differential effects of intermittent PTH(1-34) and PTH(7-34) on bone microarchitecture and aortic calcification in experimental renal failureSecreted klotho and chronic kidney diseaseCalcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift?Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HClPotential for vitamin D receptor agonists in the treatment of cardiovascular disease.Vitamin D, vitamin D analogs (deltanoids) and prostate cancer.Emerging drugs for secondary hyperparathyroidism.Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide.Extracellular calcium-sensing receptor activation induces vitamin D receptor levels in proximal kidney HK-2G cells by a mechanism that requires phosphorylation of p38alpha MAPK.Pharmacokinetics of a New Oral Vitamin D Receptor Activator (2-Methylene-19-Nor-(20S)-1α,25-Dihydroxyvitamin D3) in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism on Hemodialysis.
P2860
Q30408489-41B80AF4-64EF-41F0-9406-CEB87AC4ED75Q30418571-E25995EF-6CB5-4A63-9690-289703047466Q33809841-83B5464B-AD95-422F-94EC-FA4DE5F57637Q33862710-97E5F694-6E27-4A8C-BDE7-BE0A378B7D97Q33920663-348D4BEB-AB5D-4248-96DC-6DC0346A5222Q34790604-5D116E89-8A45-4BB9-991A-EB806D3A4FE3Q35026640-B3CD6F03-E421-4D45-8466-8142597C215CQ35189516-2BC8FF22-C034-48E1-A9DC-383717B240B5Q35843077-2158BB3C-E080-46A1-8920-214B147FF46BQ36148105-CAB6D22D-5C4D-4E37-8FBD-9F312F2E0C97Q36787402-A65BCDCF-7555-4F13-B1F3-E298128DB4E6Q36938843-6B966B2E-CC21-4B01-B8F8-BF7A4A0E691CQ36947319-6FD176D0-F791-4A39-9A6F-8DA33C07D9B4Q36949233-099B3966-DCFF-4103-BA2F-AC34B54E8FAAQ37101624-03323E83-9BE3-4158-B549-B71255FD043CQ37190542-F0059732-9F76-4968-A8C7-D796FA1A0EDFQ37310824-5704284E-E1F6-4FF2-B9F5-040628564669Q37330326-904474AE-037E-4CFE-A5AC-45182350319BQ37376932-57ABEA7F-888A-47A9-9B9D-29E66B3CDC13Q38177358-AB137ED3-34FA-4FB4-A2A0-76FEF55AE122Q38363615-E7EE72C8-AB54-4B33-9D9B-8C4F8EB8D0BBQ39374348-05B5E734-C701-4380-ACEC-C3E3D1A49A46Q40059362-C6A3493E-1E4E-42C0-9873-6E144306BAE4Q47187281-D12DD5B0-D98C-474A-894E-CFF1DCD17D69
P2860
Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Drug insight: vitamin D analog ...... s with chronic kidney disease.
@ast
Drug insight: vitamin D analog ...... s with chronic kidney disease.
@en
type
label
Drug insight: vitamin D analog ...... s with chronic kidney disease.
@ast
Drug insight: vitamin D analog ...... s with chronic kidney disease.
@en
prefLabel
Drug insight: vitamin D analog ...... s with chronic kidney disease.
@ast
Drug insight: vitamin D analog ...... s with chronic kidney disease.
@en
P356
P1476
Drug insight: vitamin D analog ...... s with chronic kidney disease.
@en
P2093
Alex J Brown
Eduardo Slatopolsky
P2860
P304
P356
10.1038/NCPENDMET0394
P577
2007-02-01T00:00:00Z